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Case Report
Introduction
Small cell carcinomas (SCCs) are aggressive neoplasms com-
monly associated with a pulmonary origin. However, albeit 
rare, extrapulmonary SCC (EPSCC) can occur in a variety of 
sites with an incidence in North America approximated to be 
0.1% to 0.4%.1 Among these sites, approximately 10% of 
EPSCC cases occur in the prostate2,3 and are associated with a 
poor survival, with a median survival of 10 months.3,4 Because 
of the rarity of the prostatic SCC, there is no formal treatment 
protocol. Current treatment is based on studies of pulmonary 
SCC, using a combined chemoradiotherapeutic approach with 
radical prostatectomy as an adjunct in only a few selected 
cases.5-8 With the poor outcome of this aggressive subtype of 
prostate cancer, further studies can help improve treatment 
outcomes. Here, we present a case of limited-stage pure SCC 
of the prostate treated with a total cystoprostatectomy and 
adjuvant chemoradiotherapy.
Case Report
A 60-year-old Caucasian male presented with episodes of 
urinary retention, a normal digital rectal examination, and 
no other urinary symptoms. His past medical history was 
significant for a high-grade T1 transitional cell carcinoma of 
the bladder 1 year prior, as well as another T1 transitional 
cell carcinoma of the bladder 7 months after the first tumor 
was diagnosed. For the first tumor, he successfully under-
went transurethral resection of the tumor and 6 cycles of 
intravesical bacillus Calmette-Guerin (BCG) immunother-
apy. The same treatment plan was given for his second 
tumor, but he developed BCG-osis after the fourth cycle. He 
underwent close follow-up by his urologist with abdominal/
pelvic computed tomography (CT) scans and urine cytol-
ogy. Three months later, around the onset of his urinary 
retention, imaging showed thickening of his bladder wall, 
and urine cytology was positive for malignancy. Furthermore, 
on bimanual examination, a firm, but moveable mass was 
palpated. With these new findings, the patient was recom-
mended cystoscopy with transurethral resection of the pros-
tate to investigate a suspected recurrence of bladder cancer 
and to provide relief of his obstructive symptoms. The 
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Abstract
Small cell carcinomas (SCCs) are aggressive neoplasms commonly associated with a pulmonary origin. However, albeit rare, 
extrapulmonary SCC can occur in a variety of sites with an incidence in North America approximated to be 0.1% to 0.4%. 
Among these sites, approximately 10% of extrapulmonary SCC cases occur in the prostate and are associated with a poor 
mortality with a median survival of 10 months. Because of the rarity of the prostatic SCC, there is no formal treatment 
protocol. In this case report, we present a patient who was diagnosed with SCC in the prostate as primary origin. Adjuvant 
concurrent chemoradiotherapy was started, which he is tolerating so far. While the management of metastatic disease is 
well documented with the use of chemotherapy, specific data on nonmetastatic disease is lacking. As some studies suggest, a 
combined surgical and chemotherapeutic approach is helpful in localized disease. In our case, this approach has led to a good 
clinical outcome in a disease that does not usually allow such results.
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procedure relieved not only the patient’s urinary retention 
but also revealed a fleshy mass occupying the right lobe of 
the prostate and no bladder masses. The pathologist reported 
the transrectal ultrasound-guided prostate biopsy to be con-
sistent with a small cell neuroendocrine carcinoma. High-
power evaluation (400×) demonstrated tumor cells with 
hyperchromatic nuclei, no nucleoli, scant cytoplasm, and 
nuclear molding, with numerous mitoses (Figure 1). The 
tumor has neuroendocrine features as shown by positivity 
with antibodies to CD5 (Figure 2) and synaptophysin 
(Figure 3).
Immunohistochemical stains were found to be positive 
for P53, CK7, and AE1/AE3 (Figures 4-6) but negative for 
staining with antibodies to chromogranin A, CK20, PSA, 
uroplakin III, GATA-3, and LCA (data not shown).
The specimen was also compared with the patient’s previ-
ous bladder biopsy and determined to be morphologically dis-
similar. Further staging workup was obtained with positron 
Figure 1. The tumor is composed of cells with hyperchromatic 
nuclei, no nucleoli, scant cytoplasm, and nuclear molding, with 
numerous mitoses (hematoxylin-eosin, 400×).
Figure 2. The tumor has neuroendocrine features as shown by 
positivity with antibodies to CD56 (400×).
Figure 3. The tumor has neuroendocrine features as shown by 
positivity with antibodies to synaptophysin (400×).
Figure 4. p53 mutation is shown by positive nuclear staining 
with antibody to p53 (400×).
Figure 5. The tumor is a carcinoma as evidenced by positivity 
with antibodies to CK7 (400×).
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emission tomography (PET)/CT scan and with magnetic reso-
nance imaging of the pelvis–neither of which revealed obvi-
ous lymphadenopathy or extraprostatic spread. Considering 
the localized nature of the tumor, the patient underwent a 
robotic-assisted total cyst prostatectomy with lymph node 
sampling of the right and left obturator lymph nodes. Final 
pathology report confirmed a submucosal small cell neuroen-
docrine carcinoma in the prostatic base, 3.5 cm at its greatest 
dimension, with involvement of the bladder neck and trigone 
area. One of the 2 lymph nodes were positive for metastatic 
carcinoma, and final pathologic staging was determined to be 
T3aN1M0. He underwent adjuvant concurrent chemoradio-
therapy with cisplatin/etoposide. The patient completed 4 
cycles and at last follow-up, 12 months after diagnosis, is tol-
erating the treatment well with negative CT imaging for 
recurrence.
Discussion
Although the prostate is one of the common site for 
EPSCC, it is a rare prostatic malignancy.2,3,9 Of these 
cases, only about 35% are pure SCC of the prostate, with 
the rest having concurrent adenocarcinomatous compo-
nents,5 but it is currently unknown whether this patho-
logical difference affects the management or prognosis. 
SCC of the prostate is reported to be more prevalent in 
the elderly with over 70% of patients being over the age 
of 65.10 Unlike prostate adenocarcinomas, most patients 
with SCC of the prostate are symptomatic. The most fre-
quently reported symptoms are obstructive symptoms, 
pressure-related neurological symptoms, or constitu-
tional symptoms, with 10% of cases present with para-
neoplastic symptoms.9,11 Depending on the tumor 
involvement, other clinical features include bone pain, 
hydronephrosis, abdominal pain, hematochezia, and 
hematuria. Imaging of the pelvis is generally nonspecific 
and serum prostate-specific antigen levels often remain 
within normal ranges.5 Ultimately, SCC of the prostate is 
diagnosed by pathological analysis of morphology and 
immunohistochemistry.3,5,11
Much of our current treatment approach to prostatic 
SCC are extrapolated from studies on the management of 
pulmonary SCC. In the limited studies available on the 
management of prostatic SCC, the recommended first-line 
treatment is chemotherapy with a combined use of cispla-
tin and etoposide because of its comparatively higher effi-
cacy rate.5,6,11 However, most of these cases are patients 
with metastatic or extensive-stage prostatic SCC, the 
more common presentation of the tumor. With respect to 
nonmetastatic or limited-stage prostatic SCC, a couple of 
studies recommend prostatectomy with adjuvant chemo-
therapy, but this approach is controversial.2,5,12 Most stud-
ies report using chemotherapy as the first-line treatment 
regardless if the tumor is metastatic or not; hence, it is 
difficult to properly assess the efficacy of a surgical ther-
apy with adjuvant chemotherapy. Several studies have 
reported that prostatectomy alone is not effective.5,8,13 In 
these localized tumors, as in our case, it would be logical 
to remove the tumor to potentially prevent possible metas-
tases and use adjuvant chemotherapy to treat possible 
occult metastases.
Conclusion
SCC of the prostate is an aggressive tumor that is associated 
with a high mortality. While the management of metastatic 
disease is well documented with the use of chemotherapy, 
specific data on nonmetastatic disease are lacking. As some 
studies suggest, a combined surgical and chemotherapeutic 
approach is helpful in localized disease. In our case, this 
approach has led to a good clinical outcome in a disease that 
does not usually allow such results.
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Figure 6. The tumor is a carcinoma as evidenced by positivity 
with antibodies to cytokeratin AE1/AE3 (400×).
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